Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 12.38B 10.71B 10B 9.17B 17.26B 1,178B 17.53B 117B 46.05B 591B 46.49B 45.48B 1,953B P/E 2026 *
-24.9x
P/E 2027 * -18.8x
Enterprise Value 11.55B 9.99B 9.33B 8.56B 16.1B 1,099B 16.35B 109B 42.96B 551B 43.37B 42.42B 1,821B EV / Sales 2026 *
24.8x
EV / Sales 2027 * 36.3x
Free-Float
94.55%
Yield 2026 *
-
Yield 2027 * -
1 day+2.12%
1 week+3.54%
Current month+3.54%
1 month+2.23%
3 months+20.58%
6 months+35.85%
Current year+32.02%
1 week 81.61
Extreme 81.61
90.81
1 month 69.88
Extreme 69.88
95.49
Current year 54.02
Extreme 54.02
95.49
1 year 15.81
Extreme 15.81
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap.
6/15/26 Free

Director

11,882 0.0084%
3/5/26 Sell

Chief Technology Officer

10,000 0.0071%
1/6/26 Don

Chief Operating Officer

77,500 0.0571%
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+3.54%+433.80%+218.84% 12.38B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.67%+10.87%+91.98%+208.74% 27.59B
Weighted average by Cap. +4.26%+12.67%+67.88%+170.73%

Financials

2026 *2027 *
Net sales 466M 403M 377M 345M 650M 44.37B 660M 4.42B 1.73B 22.24B 1.75B 1.71B 73.52B 322M 279M 260M 239M 449M 30.68B 456M 3.05B 1.2B 15.38B 1.21B 1.18B 50.83B
Net income -507M -438M -409M -375M -706M -48.22B -717M -4.8B -1.88B -24.17B -1.9B -1.86B -79.9B -676M -584M -546M -501M -942M -64.29B -956M -6.4B -2.51B -32.22B -2.54B -2.48B -107B
Net Debt -832M -720M -672M -617M -1.16B -79.22B -1.18B -7.89B -3.1B -39.71B -3.13B -3.06B -131B -683M -591M -552M -506M -952M -64.98B -967M -6.47B -2.54B -32.57B -2.56B -2.51B -108B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-08-07 US$87.65 +2.12% 948,274
26-08-06 US$85.83 -1.24% 1,051,271
26-08-05 US$86.91 -2.99% 1,703,440
26-08-04 US$89.59 +4.16% 2,031,153
26-08-03 US$86.01 +1.61% 1,268,708
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
87.65USD
Average target price
110.18USD
Spread / Average Target
+25.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock